Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $20.6552W HIGH $43.25
Volume
754.99 K
Value Traded
34.31 M
Short % Float
5.31%
-0.29%Week
-17.59%1 Month
-11.32%3 Month
+16.79%6 Month
+33.64%5 Year
+18.72%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.03 B
EPS (TTM)
-3.18
P/E Ratio
-
Ent. Value
1.66 B
Total Shares
65.41 M
Float Shares
33.60 M
Insiders
51.90%
Institutions
47.94%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
PHVS Catalyst Timeline
Dated clinical, regulatory and corporate events for Pharvaris N.V.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Pharvaris N.V.
380Total events
19Upcoming
59Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲PublicationDeucrictibantFiledPresentation
RAPIDe-3 Phase 3 results published in The Lancet
hereditary angioedema (HAE) attackssource ↗
●PublicationPresentation
Real-world HAE disease management analysis published in Advances in Therapy
hereditary angioedema (HAE)source ↗
▲Primary Endpoint MetDeucrictibantFiledClinical Data
CHAPTER-3 pivotal Phase 3 topline: primary endpoint met with 83% attack rate reduction vs placebo (p<0.0001)
hereditary angioedema (HAE) prophylaxissource ↗
●Oral PresentationDeucrictibantFiledPresentation
Conference call and webcast to discuss CHAPTER-3 topline data
hereditary angioedema (HAE)source ↗
▲Topline ReadoutDeucrictibantFiledClinical Data
Pharvaris announces positive topline data from CHAPTER-3 pivotal Phase 3 study of deucrictibant XR for HAE prophylaxis
hereditary angioedema (HAE) prophylaxissource ↗
▲Trial CompletionDeucrictibantFiledTrial
CHAPTER-3 pivotal Phase 3 study completed
hereditary angioedema (HAE)source ↗
▲Secondary Endpoint DataDeucrictibantFiledClinical Data
All secondary efficacy endpoints met with statistical significance in CHAPTER-3
hereditary angioedema (HAE) prophylaxissource ↗
▲Safety Data UpdateDeucrictibantFiledClinical Data
Deucrictibant XR well tolerated in CHAPTER-3; no treatment-related serious adverse events
hereditary angioedema (HAE) prophylaxissource ↗
●Oral PresentationDeucrictibantFiledPresentation
Oral presentation on CHAPTER-1 OLE study long-term prophylactic treatment improving disease control and HRQoL at Bradykinin Symposium 2026
hereditary angioedemasource ↗
●Poster PresentationDeucrictibantFiledPresentation
Poster presentation on NHP bradykinin challenge model predicting human efficacious doses at Bradykinin Symposium 2026
bradykinin-mediated angioedemasource ↗
●Oral PresentationPresentation
Oral presentation on LC-MS plasma proteomics in bradykinin-mediated angioedema at Bradykinin Symposium 2026
bradykinin-mediated angioedemasource ↗
●PublicationPresentation
Publication of qualitative study on AAE-C1INH disease burden and PRO validation in Frontiers in Immunology
AAE-C1INHsource ↗
●PublicationPresentation
Publication in Clinical Reviews in Allergy & Immunology summarizing evidence for bradykinin B2 receptor as therapeutic target
bradykinin-mediated angioedemasource ↗
▲FDA Filing AcceptedDeucrictibantFiledRegulatory Filing
FDA accepts NDA for deucrictibant IR for on-demand treatment of HAE attacks
Hereditary Angioedema (HAE)source ↗
▲Primary Endpoint MetDeucrictibantFiledClinical Data
RAPIDe-3 met primary and all 11 secondary endpoints with statistical significance
Hereditary Angioedema (HAE) attackssource ↗
◆Topline ReadoutDeucrictibantFiledClinical Data
Topline data from CHAPTER-3 (prophylaxis) anticipated
hereditary angioedema (HAE)source ↗
◆Topline ReadoutDeucrictibantFiledClinical Data
Topline data anticipated for CHAPTER-3 Phase 3 study of deucrictibant extended-release tablet for prevention of HAE attacks
hereditary angioedema (HAE) attacks preventionsource ↗
◆Topline ReadoutDeucrictibantFiledClinical Data
Topline data from CHAPTER-3 expected in 3Q2026
prophylaxis of HAE attackssource ↗
◆Poster PresentationDeucrictibantFiledPresentation
RAPIDe-3 Patient Voices: Qualitative Insights from the Phase 3 Study of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks
hereditary angioedemasource ↗
▲Oral PresentationDeucrictibantFiledPresentation
Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: End of Progression Results in the Phase 3 RAPIDe-3 Trial
hereditary angioedemasource ↗
▲Poster PresentationDeucrictibantFiledPresentation
CHAPTER-1 Open-Label Extension Study: Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema
hereditary angioedemasource ↗
●Poster PresentationPresentation
A Clinically Validated Kinin Biomarker Assay to Differentiate Bradykinin-Mediated from Mast Cell-Mediated Angioedema
bradykinin-mediated angioedemasource ↗
●Oral PresentationPresentation
2026 RBC Capital Markets Global Healthcare Conference Fireside Chat
▲Oral PresentationDeucrictibantFiledPresentation
Data evaluating safety margins of deucrictibant IR + XR presented at CIIC Spring 2026 Conference
hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH)source ↗
▲Enrollment CompleteDeucrictibantFiledTrial
Enrollment completed in CHAPTER-3 pivotal study of deucrictibant XR for prophylactic treatment of HAE attacks
hereditary angioedema (HAE)source ↗
●Enrollment UpdateDeucrictibantFiledTrial
Enrollment ongoing in CREAATE pivotal study of deucrictibant for prophylactic and on-demand treatment of AAE-C1INH attacks
acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH)source ↗
▲Oral PresentationDeucrictibantFiledPresentation
Data from RAPIDe-3 presented at AAAAI 2026 Annual Meeting
hereditary angioedema (HAE)source ↗
◆Topline ReadoutDeucrictibantFiledClinical Data
Anticipated Phase 3 data readout of CHAPTER-3
hereditary angioedema (HAE)source ↗
▲PublicationDeucrictibantFiledPresentation
RAPIDe-1 results published in The Lancet Haematology
hereditary angioedema (HAE) attackssource ↗
▲Full ResultsDeucrictibantFiledClinical Data
Publication of CHAPTER-1 Phase 2 results in The Lancet Haematology
hereditary angioedema (HAE)source ↗
▲Topline ReadoutDeucrictibantFiledClinical Data
Topline data from RAPIDe-3 Phase 3 on-demand study (already presented at AAAAI 2026)
hereditary angioedema (HAE)source ↗
▲Oral PresentationDeucrictibantFiledPresentation
Presentation of RAPIDe-3 data at AAAAI 2026 Annual Meeting
hereditary angioedema (HAE)source ↗
●Trial InitiationDeucrictibantFiledTrial
CREAATE Phase 3 study ongoing for prophylactic and on-demand treatment of AAE-C1INH attacks
acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH)source ↗
◆Poster PresentationDeucrictibantFiledPresentation
Poster at AAAAI: Sustained Therapeutic Exposure with Once-Daily Oral Deucrictibant Extended-Release Tablet for Prophylaxis of HAE
hereditary angioedema (HAE)source ↗
▲Poster PresentationDeucrictibantFiledPresentation
Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Final Results of the Phase 2 CHAPTER-1 Open-Label Extension Study
hereditary angioedema (HAE)source ↗
▲Primary Endpoint MetDeucrictibantFiledClinical Data
RAPIDe-3 met primary endpoint of median time to onset of symptom relief
hereditary angioedema (HAE)source ↗
◆Oral PresentationDeucrictibantFiledPresentation
AAAAI oral: Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Health-Related Quality of Life in HAE: Final Results of CHAPTER-1 OLE
hereditary angioedema (HAE)source ↗
◆Oral PresentationPresentation
Oral presentation at AAAAI: A Novel Kinin Biomarker Assay for Characterization of Different Types of Bradykinin-Mediated Angioedema
bradykinin-mediated angioedemasource ↗
Past FDA Catalysts and PDUFA Decisions
How PHVS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | deucrictibant extended-release tablet | Phase 3 topline data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D39 / 100
Pipeline Score
$217M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 42%
Small Cap(rank 277 of 658)
Percentile Rank
Pharvaris N.V. faces pipeline headwinds (39/100), with $359M risk-adjusted pipeline value, led by Deucrictibant in Hereditary Angioedema (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Deucrictibant Small moleculeNCT07266805 | Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH) | Phase 3 | RECRUITING | 48 | Jun 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every PHVS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| deucrictibant IR Orphan | hereditary angioedema (HAE) attacks | Phase 3 | 2026-10-08 | 1.28 hours; 11.95 hoursRead More | Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The LancetRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Monges VivianeDirector | Option | 11,969 17,469 held | $8.05 | 09/23/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PHVS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | 5.5 % (-19.1 %) | 92.52 M | 2.68 M |
PHVS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-12-18 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PHVS ranks across every disease it competes in
Competitive Position is a premium feature
See how PHVS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPHVS News
PHVS▼ -0.1%today
Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet
Pharvaris announced positive results from the Phase 3 RAPIDe-3 study of deucrictibant IR for treating hereditary angioedema (HAE) attacks, demonstrating faster symptom relief and resolution compared to placebo. The study met all primary and secondary endpoints with a well-tolerated safety profile. Regulatory reviews for the drug are currently underway.
Read more →PHVSReal-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy
Pharvaris announced the publication of a real-world analysis on hereditary angioedema (HAE) management, highlighting treatment gaps and patient satisfaction issues. The study, based on a multinational dataset, reveals that while multiple treatment options exist, adherence and satisfaction remain challenges. Insights from both patients and physicians underscore the need for improvements in treatment delivery and decision-making.
Read more →PHVS▲ +7.3%on this news
Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks
Pharvaris announced positive topline results from its CHAPTER-3 pivotal Phase 3 study of deucrictibant XR, demonstrating an 83% reduction in the attack rate of hereditary angioedema (HAE) compared to placebo. The study met all primary and secondary endpoints with statistical significance, indicating its efficacy and safety. Pharvaris plans to submit marketing authorization applications in 2027.
Read more →PHVSPharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026
Pharvaris presented key findings at the Bradykinin Symposium 2026, highlighting the efficacy of deucrictibant in treating bradykinin-mediated angioedema. The data showcased the drug's potential benefits, including faster symptom relief and improved patient quality of life. The findings support the ongoing development of deucrictibant as a therapeutic option for hereditary angioedema.
Read more →PHVS▲ +5.9%on this news
Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update
Pharvaris has reported its financial results for Q2 2026 and provided a business update. The company anticipates topline data from the pivotal Phase 3 CHAPTER-3 study of deucrictibant XR for HAE prophylaxis in the third quarter of 2026. Additionally, the NDA for deucrictibant IR is currently under FDA review, with a PDUFA date set for April 23, 2027.
Read more →PHVSAssessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology
Pharvaris announced the publication of a study assessing the burden of AAE-C1INH and validating patient-reported outcome measures. The findings are pivotal for the ongoing Phase 3 CREAATE study, focusing on the treatment of AAE-C1INH attacks. The study highlights the significant challenges faced by patients, including frequent misdiagnoses and a lack of approved therapies.
Read more →PHVSPublication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
Pharvaris announced the publication of a review in Clinical Reviews in Allergy & Immunology, detailing the role of the bradykinin B2 receptor in bradykinin-mediated angioedema. The article supports B2R antagonism as a therapeutic strategy, highlighting its potential across various immunological conditions. The review is based on decades of research and clinical evidence.
Read more →PHVSPharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
Pharvaris announced that the FDA has accepted its New Drug Application for deucrictibant IR, an oral treatment for hereditary angioedema (HAE) attacks. The NDA includes positive clinical data showing rapid symptom relief and a favorable safety profile. The FDA has set a PDUFA action date for April 23, 2027. If approved, deucrictibant IR will be the first oral bradykinin B2 receptor antagonist for HAE.
Read more →PHVSData Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026
Pharvaris presented data on deucrictibant at the EAACI Annual Congress 2026, highlighting its differentiated profile for managing hereditary angioedema (HAE). The Phase 3 RAPIDe-3 study showed rapid symptom relief and high efficacy with a single capsule. The drug also demonstrated a favorable cardiovascular safety profile, supporting its potential as a new standard of care.
Read more →PHVSPharvaris Announces Annual General Meeting of Shareholders
Pharvaris has announced its annual general meeting of shareholders scheduled for June 26, 2026. The meeting will provide shareholders with relevant documents and information, which can be accessed on the company's website and the SEC's site. Pharvaris is focused on developing oral therapies for bradykinin-mediated diseases, with ongoing Phase 3 studies for its treatment candidates.
Read more →PHVSPharvaris to Present Clinical Data at the EAACI Annual Congress 2026
Pharvaris (Nasdaq: PHVS) will present clinical data at the EAACI Annual Congress 2026, showcasing its research on oral bradykinin B2 receptor antagonists for treating hereditary angioedema. The company has one oral presentation and seven abstracts for flash talks/posters scheduled during the event. Notable presentations include results from the Phase 3 RAPIDe-3 trial and insights from the CHAPTER-1 study.
Read more →PHVS▲ +5.4%on this news
Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update
Pharvaris has announced its financial results for Q1 2026, highlighting a successful capital raise and ongoing clinical programs. The company is preparing for the potential launch of deucrictibant, a novel treatment for bradykinin-mediated diseases. Upcoming data from the CHAPTER-3 trial is anticipated in Q3 2026, supporting their strategic focus on these late-stage programs.
Read more →PHVSPharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Pharvaris N.V. has successfully closed an underwritten offering of 4,455,863 ordinary shares, raising approximately $132.3 million. The offering included the full exercise of an option by underwriters to purchase additional shares. The funds will support Pharvaris's development of oral bradykinin B2 receptor antagonists for treating bradykinin-mediated diseases. The company is preparing for marketing applications and has ongoing Phase 3 studies.
Read more →PHVSPharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares
Pharvaris N.V. has priced an underwritten offering of 3,874,664 ordinary shares at $29.68 each, aiming to raise approximately $115 million. The offering, which is expected to close on May 11, 2026, will fund the company's ongoing clinical development of bradykinin B2 receptor antagonists for treating hereditary angioedema and acquired angioedema. The underwriters have an option to purchase additional shares, enhancing the offering's potential.
Read more →PHVSEvidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
Pharvaris presented data at the CIIC Spring 2026 Conference supporting the combined use of deucrictibant immediate-release (IR) and extended-release (XR) formulations for treating bradykinin-mediated diseases. The analysis indicated adequate safety margins for this combination, while a post-hoc analysis suggested potential efficacy in managing breakthrough attacks. The company is advancing its clinical development of deucrictibant, aiming to improve treatment options for patients.
Read more →PHVSPharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Pharvaris reported its financial results for Q4 and full year 2025, highlighting the completion of enrollment in the pivotal CHAPTER-3 study for deucrictibant XR. The company remains on track for the NDA submission of deucrictibant IR in 1H2026. Financially, Pharvaris holds €292 million in cash, although it reported a significant annual loss.
Read more →PHVSEvidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology
Pharvaris announced the publication of two Phase 2 studies in The Lancet Haematology, demonstrating the efficacy and safety of deucrictibant for treating hereditary angioedema (HAE). The CHAPTER-1 study showed significant reduction in attack occurrences, while RAPIDe-1 indicated effective symptom relief. Both studies support deucrictibant's potential as a novel oral therapy for HAE management.
Read more →PHVSDeucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026
Pharvaris presented positive data on deucrictibant at the AAAAI 2026 Annual Meeting, highlighting its efficacy in treating hereditary angioedema (HAE) attacks. The Phase 3 RAPIDe-3 study demonstrated rapid symptom relief and significant improvements in patient outcomes. Additionally, long-term safety data from the CHAPTER-1 study support its use as a prophylactic treatment.
Read more →PHVSPharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting
Pharvaris announced the acceptance of six abstracts for poster presentations at the AAAAI 2026 Annual Meeting. This includes positive results from the RAPIDe-3 study and final data from the Phase 2 CHAPTER-1 study on deucrictibant for hereditary angioedema. The presentations will showcase significant findings and further support the ongoing Phase 3 study of deucrictibant.
Read more →About Pharvaris N.V.
BIOPHARMAWATCH ELITE PLUS
Trade the next PHVS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime